Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds
SUNNYVALE, Calif., Aug. 30, 2023 /CNW/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTC-BB:CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces the development of a process to produce corticosteroids at significantly reduced cost by utilizing its BioOxi™ platform for efficient bio-hydroxylation that can transform manufacturing.
Read more at newswire.ca